A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors

Abstract excerpt

Abstract Purpose: While immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer by producing durable antitumor responses, only 10%–30% of treated patients respond and the ability to predict clinical benefit remains elusive. Several studies, small in size and using variable analytic methods, suggest the gut microbiome may be a novel, modifiable biomarker for tumor response rates, but the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Gut microbiota and health
• Share to Inflammatory Biomarkers in Disease Prognosis